Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CABANASDAQ:CMPINASDAQ:IPHANASDAQ:OPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$1.73-7.5%$1.59$0.99▼$9.25$94.64M2.811.64 million shs3.33 million shsCMPICheckmate Pharmaceuticals$10.50$10.46$2.00▼$10.50$231.40M-4.81142,261 shsN/AIPHAInnate Pharma$1.90-1.0%$2.09$1.29▼$3.51$177.03M0.26186,471 shs4,654 shsOPTOpthea$3.41+7.2%$3.41$1.79▼$6.30$524.84M1.1226,649 shs3,000 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio-7.24%-1.14%-9.90%-1.14%-79.28%CMPICheckmate Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IPHAInnate Pharma+1.60%-3.85%-8.65%-3.31%-5.94%OPTOpthea0.00%0.00%0.00%0.00%+82.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCABACabaletta Bio2.7916 of 5 stars4.51.00.00.02.50.80.6CMPICheckmate PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIPHAInnate Pharma2.6179 of 5 stars3.85.00.00.00.61.70.0OPTOpthea0.6489 of 5 stars2.10.00.00.00.80.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCABACabaletta Bio 3.00Buy$18.88991.04% UpsideCMPICheckmate Pharmaceuticals 0.00N/AN/AN/AIPHAInnate Pharma 3.50Strong Buy$11.00478.95% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideCurrent Analyst Ratings BreakdownLatest CMPI, CABA, IPHA, and OPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025CABACabaletta BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/16/2025CABACabaletta BioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $13.005/15/2025CABACabaletta BioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $25.004/24/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.004/1/2025CABACabaletta BioWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.00 ➝ $3.004/1/2025CABACabaletta BioUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $7.004/1/2025CABACabaletta BioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/1/2025CABACabaletta BioMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$30.00 ➝ $22.004/1/2025CABACabaletta BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/28/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.503/25/2025OPTOptheaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$12.00 ➝ $2.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCABACabaletta BioN/AN/AN/AN/A$3.12 per shareN/ACMPICheckmate PharmaceuticalsN/AN/AN/AN/A$2.50 per shareN/AIPHAInnate Pharma$21.77M8.05N/AN/A$0.11 per share17.27OPTOpthea$87.67K5,986.77N/AN/A($0.56) per share-6.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCABACabaletta Bio-$115.86M-$2.54N/AN/AN/AN/A-78.29%-65.68%8/6/2025 (Estimated)CMPICheckmate Pharmaceuticals-$61.40M-$2.92N/AN/AN/AN/A-83.92%-74.99%N/AIPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/AN/AOPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/A8/28/2025 (Estimated)Latest CMPI, CABA, IPHA, and OPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025CABACabaletta Bio-$0.67-$0.71-$0.04-$0.71N/AN/A3/31/2025Q4 2024CABACabaletta Bio-$0.65-$0.65N/A-$0.65N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCABACabaletta BioN/AN/AN/AN/AN/ACMPICheckmate PharmaceuticalsN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCABACabaletta BioN/A3.963.96CMPICheckmate PharmaceuticalsN/A5.205.20IPHAInnate Pharma2.522.602.60OPTOptheaN/A1.57N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCABACabaletta BioN/ACMPICheckmate Pharmaceuticals74.56%IPHAInnate Pharma0.16%OPTOpthea55.95%Insider OwnershipCompanyInsider OwnershipCABACabaletta Bio11.25%CMPICheckmate Pharmaceuticals62.60%IPHAInnate Pharma31.89%OPTOpthea3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCABACabaletta Bio5050.74 million45.03 millionOptionableCMPICheckmate Pharmaceuticals2822.04 million8.24 millionNot OptionableIPHAInnate Pharma22092.18 million62.78 millionNot OptionableOPTOpthea8153.91 million148.99 millionNot OptionableCMPI, CABA, IPHA, and OPT HeadlinesRecent News About These CompaniesAnalysts Set Opthea Limited (NASDAQ:OPT) Target Price at $1.33June 12, 2025 | americanbankingnews.comOpthea Limited (NASDAQ:OPT) Given Average Recommendation of "Hold" by BrokeragesJune 9, 2025 | marketbeat.comOpthea (NASDAQ:OPT) Trading Up 7.2% - What's Next?June 6, 2025 | marketbeat.comOpthea Faces Leadership Changes Amidst Clinical Trial SetbacksJune 1, 2025 | tipranks.comBiotech Dimerix lands $940m licensing deal for kidney drug salesMay 1, 2025 | afr.comPhil King’s Regal successfully bets against Tesla, NvidiaMay 1, 2025 | afr.com'No one is happy': Regal stockpickers face financial hit after Opthea blow upApril 21, 2025 | capitalbrief.comRegal’s King says his hedge funds will recover from March madnessApril 16, 2025 | afr.comRegal: Don’t catch the falling knife, wait for it to stick in the floorApril 16, 2025 | msn.comOpthea to lay off approximately 65% of companyApril 10, 2025 | ophthalmologytimes.comOpthea lays off 65% of staff after back-to-back phase 3 eye disease flopsApril 10, 2025 | fiercebiotech.comBELL POTTER SECURITIES Downgrades Opthea (CKDXF)April 9, 2025 | msn.comBELL POTTER SECURITIES Downgrades Opthea Limited - Depositary Receipt () (OPT)April 9, 2025 | msn.comASX drops as US jumbo China tariff takes effectApril 9, 2025 | afr.comOpthea Limited (CKDXF) was downgraded to a Sell Rating at Bell PotterApril 3, 2025 | markets.businessinsider.comPhil King’s Regal writes Opthea to zero and backs off risky betsApril 2, 2025 | afr.comOpthea Ends Development of Sozinibercept in Wet AMDMarch 31, 2025 | marketwatch.comLifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drugMarch 31, 2025 | endpts.comOpthea terminates COAST trial, announces ShORe trial misses endpointMarch 31, 2025 | markets.businessinsider.comOpthea scraps wet AMD program after eye drug loses out to Lucentis in latest phase 3 failMarch 31, 2025 | fiercebiotech.comOpthea discontinues development of sozinibercept in wet AMDMarch 31, 2025 | healio.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsZscaler Upgraded: Wall Street Forecasts 26% More UpsideBy Gabriel Osorio-Mazilli | June 17, 2025View Zscaler Upgraded: Wall Street Forecasts 26% More UpsideCMPI, CABA, IPHA, and OPT Company DescriptionsCabaletta Bio NASDAQ:CABA$1.73 -0.14 (-7.49%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.76 +0.02 (+1.45%) As of 06/18/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Checkmate Pharmaceuticals NASDAQ:CMPICheckmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Innate Pharma NASDAQ:IPHA$1.90 -0.02 (-1.04%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$1.88 -0.01 (-0.79%) As of 06/18/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Opthea NASDAQ:OPT$3.41 +0.23 (+7.23%) As of 06/17/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
